Skip to NavigationSkip to content

AstraZeneca jettisons European heart drug rights for $210m

Published on 24/07/18 at 08:38am

AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment Atacand (candesartan) to German pharmaceutical firm Cheplapharm Arzneimittel for $210 million.

The move to jettison European marketing efforts the ageing drug is part of AZ’s ongoing focus to streamline its portfolio and free up investment opportunities for new drugs in its key therapeutic areas. Last year, the drug and its variation, Atacand Plus, generated $300 million in global sales, with $86 million drawn from European markets.

As part of the deal, the total sum will be paid by the Anglo-Swedish firm in the form of a $200 million payment on completion of the deal – expected to close in the third quarter of this year – as well as $10 million in milestone payments, contingent on market success.  

Though it will lose the rights to the drug in Europe, AZ will continue to market it in the US and other non-European markets, and will also continue to manufacture and provide the drug as part of supply agreements.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches